Complement components and ligands

ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF 165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes

Avacincaptad pegol (ARC1905) is is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. Avacincaptad pegol is being used for the study of age-related macular degeneration (AMD).Form:Solid

BCX 1470 methanesulfonate inhibits the esterolytic activity of factor D ( IC 50 =96 nM) and C1s ( IC 50 =1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.In VitroBCX 1470 methanesulfonate is serine protease inhibitor. BCX 1470

BCX 1470 methanesulfonate inhibits the esterolytic activity of factor D ( IC 50 =96 nM) and C1s ( IC 50 =1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.In VitroBCX 1470 methanesulfonate is serine protease inhibitor. BCX 1470

BCX 1470 methanesulfonate inhibits the esterolytic activity of factor D ( IC 50 =96 nM) and C1s ( IC 50 =1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.In VitroBCX 1470 methanesulfonate is serine protease inhibitor. BCX 1470

C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.Appearance:SolidIn Vitro:The direct interaction of C3a(70-77) with human

C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.Appearance:SolidIn Vitro:The direct interaction of C3a(70-77) with human

C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.Appearance:SolidIn Vitro:The direct interaction of C3a(70-77) with human

C3a

C3a

C3a

C3a